Navigation Links
Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008

29 presentations on ZEVALIN(R) scheduled at American Society of Hematology

(ASH) Annual Meeting

SEATTLE, Nov. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced it intends to utilize the results of the phase III first-line indolent trial of ZEVALIN (Ibritumomab Tiuxetan), known as the FIT trial, for submission to the United States Food and Drug Administration (FDA) for potential approval in the consolidation of first remissions following chemotherapy for patients with follicular non-Hodgkin's lymphoma (NHL). CTI has signed an agreement to acquire the U.S. marketing, sales and development rights to ZEVALIN, however, that acquisition has not yet been completed and remains subject to closing conditions, including obtaining certain third party consents, and until the transaction is closed, ZEVALIN remains a product and trademark of Biogen Idec, Inc. CTI expects the acquisition to close by the end of November and as such is hosting a booth at the ASH meetings. The results of the FIT trial will be presented in an oral session on Monday, December 10 at 3:30 p.m. (Eastern) at the 49th Annual Meeting of the American Society of Hematology (ASH), being held December 8-11, 2007 in Atlanta.

Bayer Schering recently announced it had submitted the FIT results to the EMEA for consideration for a new indication for the product in the European Union (EU). "With our commercial leadership now on board we look forward to the prospects of working closely with Bayer-Schering in providing the support for the Zevalin brand that this important therapeutic deserves," said James A. Bianco, M.D., President and CEO of CTI.

Other presentations at ASH, include a presentation by CTI on pixantrone and 29 presentations by Biogen Idec and Bayer-Schering on ZEVALIN(R). Selected ZEVALIN presentations are included below.

Date Time Poster # Title



December 8, 5:30 #236-I The Impact of Incorporating Targeted

2007 PM (1082) Radioimmunotherapy (RIT) into

Transplant Preparative Regimens on

the Incidence of Therapy Related

Myelodysplasia (t-MDS) or AML (t-AML)

Following Autologous Stem Cell

Transplant (ASCT) for Lymphoma.

Sunday, 5:15 Oral Session 90Yttrium Ibritumomab Tiuxetan

Dec. 9, PM (22) (Zevalin) Combined with BEAM (Z -

2007 BEAM) Conditioning Regimen Plus

Autologous Stem Cell Transplantation

in Relapsed or Refractory Follicular

Lymphoma. GELA Phase II Study.

Monday, 12:00 Oral Session Phase II Study of R-CHOP Followed by

December 10, PM (389) 90Y-Ibritumomab Tiuxetan in Untreated

2007 Mantle Cell Lymphoma: Eastern

Cooperative Oncology Group Study


Monday, 3:30 Oral Session 90Y-Ibritumomab Tiuxetan (ZEVALIN)

Dec. 10, PM (643) Consolidation of First Remission

2007 in Advanced Stage Follicular

Non-Hodgkins Lymphoma: First Results

of the International Randomized Phase

3 First-Line Indolent Trial (FIT) in

414 Patients.

Monday, 5:00 #631-III Radioimmunotherapy with 90Y-

Dec. 10, PM (3412) Ibritumomab Tiuxetan (Zevalin)

2007 as Consolidation of First Remission

in Patients with Advanced Stage

Follicular Lymphoma: A Real-Time MBR

RQ-PCR Analysis.

Monday, 5:00 #664-III CHOP-R (Cyclophosphamide,

Dec. 10, PM (3445) Doxorubicin, Vincristine, Prednisone,

2007 Rituximab) Compared to CPOP-R

(Cyclophosphamide, Pixantrone,

Vincristine, Prednisone, Rituxamib)

in First-Line Therapy of Diffuse

Large B Cell Lymphoma (DLBCL): An

Interim Analysis.

For more information about the ASH annual meeting and for a complete list of abstracts, please refer to the conference Web site at


ZEVALIN(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 ZEVALIN administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the ZEVALIN therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to ZEVALIN therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). ZEVALIN should only be used by health care professionals qualified by training and experience in the safe use of radionuclides. Patients and healthcare professionals can visit for more information.

About Pixantrone

Pixantrone (BBR 2778) is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the marketing and development of ZEVALIN or the development of pixantrone, and include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with ZEVALIN and pixantrone in particular including, without limitation, the potential failure of the closing of the acquisition of ZEVALIN, the potential failure of pixantrone as a product candidate to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling ZEVALIN, and pixantrone as well as the risk that we may not be able to complete the ZEVALIN acquisition or, if the ZEVALIN acquisition is accomplished, the risk of potential failure of obtaining approval from the FDA for label expansion of ZEVALIN, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward- looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Lindsey Jesch

T: 206.272.4347

F: 206.272.4434


Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434


SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Health Plans Increase Use of Health Incentives
11. Area Health Care Providers Announce Plans to Integrate Services
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of people ... Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. “Hollister ... free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed our ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit ... full control over customization, the possibilities are truly endless, all with a click of ... depth position, vertical flip, horizontal flip, depth of field and more, all within Final ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... engine optimization companies, announced today that it has officially launched a sleek, mobile-ready ... SEO, explained that his company’s new website clearly outlines the benefits that its ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... a 2015-2016 inductee into its VIP Woman of the Year Circle. She is recognized ... nation’s leading networking organization exclusively for professional women, boasting more than 850,000 members and ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  InCarda ... the development and commercialization of therapies for cardiovascular conditions ... established a subsidiary business in Australia ... clinical trial in Australia in ... with leading investigators and medical centers in ...
(Date:12/1/2015)... and TELTOW, Germany , December ... (SMI) , a leading global manufacturer of eye and ... has included SMI remote eye trackers as a ... healthcare providers assess concussions, eye sight, and medical and ... -oem technology is part of SMI,s mass-market-ready eye tracking ...
(Date:12/1/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... 2016 as the ex-distribution date for Ampio,s previously announced ... Stock of Aytu BioScience, Inc. As announced, Ampio will ... every five (5) shares of Ampio Common Stock owned ... date will be January 4, 2016. ...
Breaking Medicine Technology: